Yishay Wasserstrum1,2, Sofia Nadav1,3, Amitai Segev1,2, Dor Lotan4, Dov Freimark1,2, Michael Arad1,2. 1. Chaim Sheba Medical Center, Tel Hashomer, Israel. 2. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. St. George School of Medicine, University of London, London, UK. 4. Division of Cardiology, Columbia University Medical Center, NewYork-Presbyterian Hospital in New York, New York, USA.
Abstract
Background: Vaccines against SARS-COV2 have been crucial in efforts against COVID19, yet there have been reports of pericarditis following vaccination with mRNA-based vaccines. Methods: We questioned consecutive patients with a history of acute pericarditis (AP) evaluated in the pericardial disease clinic during 3-11/2020 in a single tertiary center. Patients with significant myocardial involvement or pericarditis secondary to another systemic disease were excluded. Results: We included 64 patients in the final analysis. Mean age was 53.1 (±18), and 26 (41%) were female. At least 1 recurrence of AP was documented in 47 (73%) cases, 32 (50%) had ≥ 3 recurrences prior to vaccination. AP was considered to be idiopathic\viral in 45 (70%) cases, 20 (31%) cases were post-injury. All patients received at least 2 doses of the vaccine, and 48 patients (75%) received a 3rd dose. Two cases of breakthrough COVID19 infections were documented. Overall, 12 patients (19%) reported any adverse events. Of which, 2 had recurrent pericarditis. There was a trend for a younger age in those patients who had adverse events (median age 45 [IQR 36-61] vs. 60 [38-71], p = 0.08). no other significant difference was seen. Conclusion: In patients with a history of acute\recurrent pericarditis, the use of BNT162b2 was mostly uneventful, but some mild disease recurrences did occur.
Background: Vaccines against SARS-COV2 have been crucial in efforts against COVID19, yet there have been reports of pericarditis following vaccination with mRNA-based vaccines. Methods: We questioned consecutive patients with a history of acute pericarditis (AP) evaluated in the pericardial disease clinic during 3-11/2020 in a single tertiary center. Patients with significant myocardial involvement or pericarditis secondary to another systemic disease were excluded. Results: We included 64 patients in the final analysis. Mean age was 53.1 (±18), and 26 (41%) were female. At least 1 recurrence of AP was documented in 47 (73%) cases, 32 (50%) had ≥ 3 recurrences prior to vaccination. AP was considered to be idiopathic\viral in 45 (70%) cases, 20 (31%) cases were post-injury. All patients received at least 2 doses of the vaccine, and 48 patients (75%) received a 3rd dose. Two cases of breakthrough COVID19 infections were documented. Overall, 12 patients (19%) reported any adverse events. Of which, 2 had recurrent pericarditis. There was a trend for a younger age in those patients who had adverse events (median age 45 [IQR 36-61] vs. 60 [38-71], p = 0.08). no other significant difference was seen. Conclusion: In patients with a history of acute\recurrent pericarditis, the use of BNT162b2 was mostly uneventful, but some mild disease recurrences did occur.
Authors: John R Su; Michael M McNeil; Kerry J Welsh; Paige L Marquez; Carmen Ng; Ming Yan; Maria V Cano Journal: Vaccine Date: 2021-01-06 Impact factor: 3.641
Authors: Juan Guido Chiabrando; Aldo Bonaventura; Alessandra Vecchié; George F Wohlford; Adolfo G Mauro; Jennifer H Jordan; John D Grizzard; Fabrizio Montecucco; Daniel Horacio Berrocal; Antonio Brucato; Massimo Imazio; Antonio Abbate Journal: J Am Coll Cardiol Date: 2020-01-07 Impact factor: 24.094
Authors: Hui-Lee Wong; Mao Hu; Cindy Ke Zhou; Patricia C Lloyd; Kandace L Amend; Daniel C Beachler; Alex Secora; Cheryl N McMahill-Walraven; Yun Lu; Yue Wu; Rachel P Ogilvie; Christian Reich; Djeneba Audrey Djibo; Zhiruo Wan; John D Seeger; Sandia Akhtar; Yixin Jiao; Yoganand Chillarige; Rose Do; John Hornberger; Joyce Obidi; Richard Forshee; Azadeh Shoaibi; Steven A Anderson Journal: Lancet Date: 2022-06-11 Impact factor: 202.731
Authors: Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber Journal: N Engl J Med Date: 2020-12-10 Impact factor: 91.245
Authors: Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks Journal: N Engl J Med Date: 2020-12-30 Impact factor: 91.245